Neurological disorders Archives

News and Trends 25 Apr 2017

Novartis Negotiates its Way into the US Migraine Market

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed…

April 25, 2017 - 2 minutesmins - By Melanie De Almeida

In Depth 25 Apr 2017

How Biotech is Mastering Multiple Sclerosis: A Review

With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard…

April 25, 2017 - 7 minutesmins - By Diana Kwon

Mission Therapeutics Parkinsons research grant

News and Trends 11 Apr 2017

New Grant to Advance a Whole New Treatment Against Parkinson’s in the UK

Mission Therapeutics has received a grant to support the development of a novel approach to treating Parkinson's that is attracting top partners worldwide. Right on time for World Parkinson's Day today, Mission…

April 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Interview 10 Apr 2017

“Alzheimer’s is the Last Unclaimed Therapeutic Space,” says TauRx exec

The Alzheimer’s field has been hit with a number of failures. I spoke to the COO/CBO of TauRx, whose alternative approach may yet succeed. Pharma is throwing all it can…

April 10, 2017 - 7 minutesmins - By Evelyn Warner

roche morphosys antibody alzheimers gantenerumab 1

News and Trends 14 Mar 2017

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

After recent late-stage disappointments from Eli Lilly and Merck, Roche and Morphosys are stepping up with two new Phase III trials in Alzheimer's. Roche just announced plans to start two new…

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement…

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

AlzProtect crowdfunding neurodegenerative disease

News and Trends 15 Feb 2017

French Biotech bids for Crowdfunding in Neurodegenerative Disease

AlzProtect is aiming to raise €1M via equity crowdfunding to fund a Phase Ib trial in progressive supranuclear palsy (PSP). AlzProtect is a biotech in Lille, France, fighting neurodegenerative disease.…

February 15, 2017 - 2 minutesmins - By External Contributor

News and Trends 13 Feb 2017

Biotech from the Bermuda Islands Brings Good News for Dementia Patients

Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British…

February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Feb 2017

A Dutch University Hospital has Halted Amyloid Beta Drug Studies

Despite the popularity of amyloid beta-targeting drugs, none have managed to pass late stage clinical trials, prompting UMC Radboud to halt its own studies. In the latest blow to the…

February 10, 2017 - 3 minutesmins - By Diana Kwon

News and Trends 7 Feb 2017

Swiss Parkinson’s Biotech raises Massive €29M in Series B from Top European VCs

Top European VCs have invested €29M in Prexton Therapeutics to support two Phase II trials of its lead candidate foliglurax in Parkinson's. An international team of top European biotech investors…

February 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 31 Jan 2017

Biologicals on the Brain: Biotech in Neurodegenerative Disease

Brain diseases are hard to treat, but biotechs are harnessing a variety of techniques, including immunotherapy and gene therapy, to target neurodegenerative disorders. When Eli Lilly announced that solanezumab, a…

January 31, 2017 - 7 minutesmins - By Diana Kwon

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small…

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Jan 2017

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year…

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Evotec closes the year partnering with Celgene to treat Alzheimer’s

Evotec is closing a fantastic financial year with another top-level partnership; Celgene has decided to trust in its iPSC platform to develop drugs for neurodegenerative diseases. Evotec is a successful drug…

December 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Dec 2016

Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments?

Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents…

December 19, 2016 - 7 minutesmins - By Evelyn Warner

News and Trends 13 Dec 2016

European Pharma closes 2016 by launching new Biotech Startups

Big pharma is already head on starting 2017 with a bang. Pfizer and Bayer are launching US-based startups in oncolytic virus and stem cell therapies. Pharma is wrapping up 2016…

December 13, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 8 Dec 2016

Meet the Newest ALS Pioneer Company from Switzerland

AL-S Pharma was just born with the only purpose of developing a drug candidate for ALS, a rare condition for which no effective treatments exist. The parents of the newborn…

December 8, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Dec 2016

UPDATE: More Good News on a Cannabis Derivative for Epilepsy

Update (07/12/2017): GW Pharma has announced more positive Phase III results for Epidiolex, pushing the drug closer to the market and a win for supporters of legalizing marijuana. Originally published…

December 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Nov 2016

Drugging the Undruggable: New Acquisition to Boost GPCR Drugs

Heptares Therapeutics has acquired G7 Therapeutics to take control over its GPCR technology, boost its pipeline and keep competitors in this profitable field at bay. Heptares Therapeutics develops therapies directed…

November 30, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it's using its strong position to make the leap into the crowded market of multiple sclerosis…

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering